Spero Therapeutics, Inc.SPRO
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing novel antibiotics to treat resistant bacterial infections, including a broad-spectrum agent targeting gram-negative pathogens. Its pipeline centers on difficult-to-treat infections, a niche that attracts investor interest due to the growing threat of antimicrobial resistance and limited competition. The company's progress through clinical trials and regulatory milestones is closely watched by healthcare investors.
Congressional Interest in Spero Therapeutics, Inc. (SPRO)
1 member of Congress has disclosed 1 trade in Spero Therapeutics, Inc. (SPRO), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Who in Congress Is Trading SPRO?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2016-11-29 | James Comer | buy | $1K-$15K |